P434. Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: A chart review analysis
K. Bodger1, L. Yen2, A. Szende3, J. McDermott4, P. Hodgkins2, 1Digestive Diseases Centre, Aintree University Hospital, Liverpool, United Kingdom, 2Shire Development LLC, Wayne, PA, United States, 3Covance, Leeds, United Kingdom, 4Covance, Gaithersburg, MD, United States
Limited evidence is available on the economic burden of ulcerative colitis (UC) in the United Kingdom (UK), particularly relating to the impact of relapse frequency on direct medical costs. This study identifies and assesses medical resource utilization (MRU) and associated direct costs in mild and moderate UC patients in the UK.
A retrospective chart review of patients with mild-to-moderate UC diagnosed at least 1 year prior to the study was performed. From 33 general practitioner (GP) and 34 gastroenterologist (GI) sites, charts of the last 3 UC patients meeting the inclusion criteria were reviewed. Descriptive statistics were calculated for MRU and 2011 costs (British Pound; £) by number of relapses. Through logistic regression, costs were estimated while adjusting for relapse status, patient demographics, site type, and treatment setting.
Study population: N = 201 patients; mean age, 39.9 years; 44% female; mean disease duration, 7.4 years. Mean annual UC-related medical and medication costs were £1,344 (SD: £3,300) and £296 (SD: £569). Hospitalisations accounted for 35% and medications for 18% of UC-related costs. UC-related costs of each MRU category increased with the number of relapses. Comparing patients without relapse to those with more than 2 relapses, mean annual UC-related costs were £14 versus £2,556 for hospitalisations; £218 versus £988 for visits (including nurse, GP, specialist, and other visits); £21 versus £1,303 for procedures; £17 versus £188 for diagnostics, and £1,168 versus £6,660 for all-cause total costs. Age, gender, and site of data reporting (GP versus GI) were not associated with MRU or costs.
Patients with mild-to-moderate UC incurred considerable costs that increased greatly with the number of relapses. These findings support the importance of maintenance therapies in UC that reduce or prevent relapses. Quantifying the relationship between relapse rate and costs will inform future health economic studies.